8 ASX 200 stocks hit fresh 52-week lows last week (and they all have one thing in common)
Eight ASX 200 stocks that missed earnings expectations continue sliding weeks after brutal results day selloffs.
.jpg)
Source: Shutterstock
Mentioned
KEY POINTS
- Eight ASX 200 stocks including CSL, Sonic Healthcare and Domino's all missed FY25 earnings expectations and suffered average 18.8% declines on results day.
- Despite the initial brutal selloffs, seven of the eight stocks have continued falling with an average additional 9.2% decline since reporting.
- Historical data shows stocks that miss earnings typically fall 6.3% on results day then slide another 8.4% over the following four months, making buying the dip a poor strategy.
Each week, I run a simple scan for S&P/ASX 200 stocks making fresh 52-week highs and lows to identify sectors showing strong breadth and breakout momentum, which is often signals the start of a broader group advance.
Interestingly, all (except one) of this week's 52-week low list had one thing in common, despite spanning multiple sectors with vastly different fundamentals. Before I reveal what connects them, see if you can spot the pattern from the list of stocks below.
ASX 200 Stocks at 52-Week Lows
Ticker | Company | Close | Sector | 1 Week | 1 Year |
|---|---|---|---|---|---|
Reece | $10.32 | Industrials | 1.4% | -64.5% | |
Domino's Pizza | $14.01 | Discretionary | -1.1% | -56.7% | |
Bapcor | $3.21 | Discretionary | -8.0% | -36.6% | |
IPH | $3.85 | Industrials | -4.0% | -34.9% | |
CSL | $198.37 | Health Care | -4.6% | -31.6% | |
Telix Pharmaceuticals | $14.53 | Health Care | 6.1% | -29.8% | |
Ebos Group | $24.93 | Health Care | -4.7% | -27.0% | |
Sonic Healthcare | $22.43 | Health Care | -0.9% | -14.2% | |
Inghams Group | $2.52 | Staples | -4.6% | -14.0% |
S&P/ASX 200 stocks and sectors that hit 52-week lows in the past week, sorted by one-year returns. Data as at Friday, 19 September 2025.
The answer
They all (except Telix) missed FY25 earnings expectations in August and suffered a steep one-day selloff.
At a glance
The average results day decline was 18.8%, with all companies reporting some form of earnings miss, whether that be for the full-year, guidance or a specific line-item such as margins or dividends.
Here are the the results day reactions and key earnings takeaways:
Inghams (-20.2%): Inghams reported a disappointing set of results with revenue, underlying EBITDA, and underlying NPAT all missing analyst expectations by 1-8%, while also lowering its dividend and providing a weaker-than-expected earnings outlook for FY26.
Sonic Healthcare (-12.8%): FY25 NPAT was 3% below market expectations, pathology EBITDA margin of 17.7% was 60 bps below consensus and FY26 guidance was also a miss.
Ebos (-14.6%): 2H25 EBITDA was 5% below analyst expectations, with a lower-than-expected FY26 EBITDA guidance due to smaller margin on new Community Pharmacy business wins.
CSL (-16.8%): A mixed FY25 result, with its NPAT and NPATA EPS beating estimates by 1-2%, while revenue and the total dividend fell just shy of expectations. However, FY26 NPATA growth guidance of 7-10% was well-below some analyst expectations of 15-16%.
IPH (-19.5%): IPH reported mixed FY25 earnings amid ongoing structural challenges. The result flagged persistent market share losses in ANZ, weaker US filings and a slower-than-expected recovery in Asia.
Bapcor (-28.3%): Bapcor pre-released its FY25 earnings on 24 July, flagging weaker earnings, revenue pressure across all divisions and a large balance sheet review that included several material write downs.
Domino's Pizza (-21.9%): FY25 numbers were broadly in-line with market expectations, but the stock sold off on a weaker-than-expected trading update and limited disclosure on cost savings.
Reece (-16.4%): FY25 EBIT fell 20% year-on-year to $548 million, right on the low end of the company's $548-558 million guidance. While the outlook commentary suggests housing markets remain challenging in both ANZ ("slow recovery anticipated" and the US ("expect market to remain constrained for the next 12-18 months").
The data says: "Don't buy the dip"
At first glance, you might think the selloffs created buying opportunities in solid healthcare names like Sonic, Ebos and CSL, or that the sharp reactions in Inghams, Domino's and Reece had fully priced in the bad news.
That would have been a costly mistake.
While the data carries a negative bias (since they've all hit fresh 52-week lows in the past week), the initial results day reaction alone was severe enough to push most names to yearly lows. Yet despite those massive one-day selloffs, the pain has continued.
All but one stock has slid even further since reporting, down an average 9.2%.
Ticker | Company | Reporting Date | % Chg since |
|---|---|---|---|
CSL | CSL | 19-Aug | -11.50% |
IPH | IPH | 21-Aug | -16.80% |
SHL | Sonic Healthcare | 21-Aug | -11.90% |
ING | Inghams | 22-Aug | -10.90% |
REH | Reece | 25-Aug | 0.30% |
DMP | Domino's Pizza | 27-Aug | -9.60% |
EBO | Ebos Group | 27-Aug | -13.20% |
BAP | Bapcor | 28-Aug | -18.50% |
Share price performance after results day gap down to 23 September 2025
It's ugly out there
Some of the share price reactions have been absolutely brutal.
IPH suffered a massive one-day results-driven selloff, followed by a small bounce and more selling. The stock is currently on a twelve day losing streak, down 15% since 5 September.
IPH daily price chart (Source: TradingView)
This long and painful price action is similar for names like Bapcor, Ebos, Sonic Healthcare and CSL. Clearly, nobody wants to touch these stocks.
The bottom line
Heading into reporting season, I wrote a piece titled: "Make ASX reporting season easy: Buy winners, sell losers". The article referenced Bell Potter's Richard Coppleson, whose analysis showed that earnings misses typically trigger an average 6.3% decline on results day, but there's often more pain to come.
Rather than bouncing back, these underperformers tend to keep sliding, falling an additional 8.4% over the following four months.
The bottom line: if your stock gets smashed during reporting season, it's probably not a good idea to buy the dip.
